Events

Careers with impact: working in ML applied drug discovery

One of the unexpected outcomes of the COVID-19 pandemic has been that it has made technology talent aware of the opportunities to use technology to tackle some of the world’s most important and pressing healthcare challenges. 


4th November 2020 | 5.30pm UK time - 12:30pm NYC Time

While interest in joining the industry has increased, many are prevented from taking the leap due to a belief that they do not possess the necessary scientific knowledge. This invisible door is preventing talented people from entering the industry. Worryingly, this problem could be amplified for women in tech, who are already less likely to apply for a role they’re not 100% qualified for.

This meetup will look to demystify AI in drug discovery in order to empower female tech talent to take the leap into this important growth industry. We will counter preconceptions that only those with scientific knowledge can join, by showcasing how we work at BenevolentAI, where we bring together cross-functional teams of machine learning engineers, AI scientists, data scientists and informaticians to co-create our AI platform for drug discovery, alongside our seasoned drug discoverers.

This is a free event and we’d love you to join us for an evening of open dialogue and ideas exchange. 

→ Register here

Event agenda

17:30 – Grab a drink of your choice, get comfy and logon for an intro from Sam

17:35 – 19:55 – Panel discussion part I: countering preconceptions that only those with scientific knowledge can join the drug discovery industry

17:55 - 18:15 – Panel discussion part II: exploring the importance of diverse skills and experiences in AI applied drug discovery, and discussing practical actions to building diverse and inclusive teams.

18:15 - 18:20 – Q&As

18:20 - 18:50 – Split into virtual rooms for networking and a Q&A opportunity with the Benevolent team.


Speakers:

Ana Leite | Lead Bioinformatic Data Scientist

Aylin Cakiroglu | Senior AI Scientist

Paidi Creed | Director, AI Science

Saee Paliwal | Lead AI Scientist

Sam Coulter (Moderator) | Talent Acquisition Specialist


More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021